EMA Authorised: Sugammadex Mylan (sugammadex sodium) — Mylan Pharmaceuticals Limited

View source ↗

Summary

EMA authorises Sugammadex Mylan (sugammadex sodium) for reversal of neuromuscular blockade; new marketing authorisation holder is Mylan Pharmaceuticals Limited.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuromuscular Blockade Reversal Indication

Drugs mentioned

• Sugammadex Mylan (sugammadex sodium)

Snippet

Status: Authorised. Therapeutic area: Neuromuscular Blockade. MAH: Mylan Pharmaceuticals Limited. Decision date: 08/06/2026